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VALVE PROSTHESES, 
VALVES REPAIR AND HOMOGRAFTS
When damage is incompatible with preserving the valve, the
treatment of the valve disease is replacement with a prosthe-
tic valve (approximately 9,000 cases per year in France). Two
main types of prostheses exist: mechanical prostheses (which
require long term anti-coagulation although their robustness
and longevity have been widely demonstrated [1, 2]) and bio-
logical prostheses (bioprostheses) which do not require any
specific treatment but have a shorter lifespan (average 10 to
15 years) because of risk of degeneration, which occurs faster
in people under 40 years [2, 3]. Aortic and mitral valve homo-
graft implantation is not widely used. In addition, whilst mitral
valve repair techniques are making rapid advances, aortic
valve repair techniques are not widely used in France.
Normal valve prostheses, 
valve repair and homografts
These display no abnormal clinical or radiological signs of dys-
function.
Initial assessment (2 or 3 months post-operatively)
Prosthetic valves
Each type of prosthesis has specific characteristics, represen-
ting a true echocardiographic and Doppler signature, which
depend on their haemodynamic profile, position and size. This
identity card is essential for patient follow-up.
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Baseline investigation
Each recipient of a prosthetic cardiac valve must have a base-
line assessment in order to record the haemodynamic cons-
tants for the type of prosthesis implanted [4-7]: this investiga-
tion should be performed when the patient has returned to a
stable haemodynamic situation (correction of anaemia, resto-
ration of normal heart rhythm etc.) i.e. generally within two
to three months after the procedure. The first month assess-
ment must not be used as the baseline record.
The following findings are recorded in the baseline report:
date of the procedure, type and size of prosthesis implanted,
heart rhythm, any associated procedures (bypass, tricuspid
annuloplasty, other valve replacement, preservation of the
mitral subvalvular apparatus). This report can be attached to
the document describing the features of the prosthesis and
given to the patient when discharged from the surgical depart-
ment.
As for a native valve disease, the echocardiographer must
assess left ventricular function in M-mode and two-dimensio-
nal mode, the size of the different cardiac cavities and the
pulmonary pressures when accessible to Doppler mode.
As for any valve disease, the echocardiographic assessment
of a prosthetic valve is based on a combination of anatomical
findings provided by M-mode and, particularly, two-dimensio-
nal imaging and Doppler haemodynamic findings. M-mode and
two-dimensional modes are of lower value for the anatomical
analysis of mechanical prostheses than for bioprostheses and
native valves because of the reverberations caused by the
metallic structures: the motion of the discs of bileaflet pros-
theses can, nevertheless, be clearly analysed in most patients
through the quality of current imaging. The morphology of the
leaflets of bioprostheses can also be clearly assessed by 2D
imaging [8]. The anatomical assessment is still therefore a
fundamental initial stage in the echocardiographic investiga-
tion of prosthetic valves.
The assessment of prostheses also uses Doppler examina-
tion. Regardless of type, any prosthesis causes a degree of
obstruction, which varies depending on its haemodynamic pro-
file, position and size: monitoring of the prosthesis and
patient follow-up are based on recording the transprosthetic
velocities by continuous Doppler.
Colour Doppler mode occasionally allows small para- or
intraprosthetic regurgitations from aortic prostheses to be
identified [9]. 
The essential parameters to be recorded to assess mitral
prostheses (table 1), which are analysed particularly from the
apical 4 chamber view are:.the mean transprosthetic gradient which is usually of
5±3 mmHg, and clearly abnormal when above 10 mmHg. It
is relatively independent of size of prosthesis, unlike aortic
prostheses but depends mostly on the type of valve (the
lowest gradients are seen with bioprostheses and bileaflet
prostheses and the highest with ball prostheses), heart
rate, rhythm and cardiac output..the “pressure half time” (PHT) as in the case of mitral ste-
nosis. This is a simple parameter to monitor prostheses
which reflects transprosthetic diastolic filling. Only the
uncorrected value of the PHT not adjusted for prosthetic
surface area is used. It should be remembered that calcula-
ting the prosthetic surface area from the PHT (Hatle equa-
tion: mitral area = 220/PHT) has only been validated for
mitral stenosis in native valves but not for normal prosthe-
tic valves. Only the PHT value should appear on the Doppler
echocardiography reports. PHT values are normally
between 70 and 100 msec: in atrial fibrillation it varies
greatly depending on the length of diastole. A PHT >150
msec is formally pathological..the functional surface area of the prosthesis by the
continuity equation, calculated in the same way as the
mitral surface area in mitral stenosis can be used if the
patient is in sinus rhythm and if no significant concomitant
aortic valve regurgitation is present. It varies from 1.6 to
2.8 cm2..the presence of intra or para-prosthetic regurgitations: con-
tinuous-wave Doppler must be used, because colour Dop-
pler is severely affected by reverberations from the pros-
thesis. The procedure follows in reverse to usual order,
identifying regurgitations first by continuous Doppler and
then localising them with colour Doppler. Intraprosthetic
regurgitations are common: 30 to 40% by TTE and in almost
100% of cases by TOE [10-15]. They are located at the junc-
tion between the mobile part and the metallic frame of the
prosthesis: their topography is therefore characteristic of
type of prosthesis. Para-prosthetic regurgitations are relati-
vely common during the immediate post-operative period,
are usually minimal and frequently disappear spontaneously
over a few weeks.
The main parameters to record for the analysis of aortic
prostheses (table 2), which are best seen in the apical 5
chamber and right parasternal views by TTE or suprasternally
in young people are:.the maximum and mean gradients: the mean gradient is
normally between 7 and 25 mmHg and is usually pathologi-
cal above 30 mmHg. It is useful to identify opening and clo-
sing clicks of the prosthesis for a better recording of the
transprosthetic flow. The mean gradient depends on the
type of prosthesis (lower gradients are found with biopros-
theses and bileaflet mechanical prostheses and higher
values for ball prostheses), size (number) +++ and cardiac
output..the functional or “effective” surface area of the prosthesis
by the continuity equation may be calculated in the same
way as for native valves if the patient is in sinus rhythm. For
outflow tract diameter, the diameter (or number) of the
prosthesis can be used. The prosthesis surface area ranges
from 0.9 to 2.2 cm2, depending on the type and calibre of
the prosthesis. As for aortic stenosis on native valves it is
also recommended that this surface be expressed as an
index to body surface area..the permeability index (PI), which is similar to the one
used for aortic stenosis, is a simple index, independent of
cardiac output and does not require measurement of the
left ventricular outflow tract diameter. The ratio of velo-
city time integrals or maximum velocities of the outflow
tract and transprosthetic flow can be used. In atrial
fibrillation it is essential to take into account the subaor-
tic flow and transprosthetic flow on the same cycle by
continuous Doppler. Normal PI values vary depending on
the type and diameter of prosthesis: they increase with
decreasing physiological obstruction from the prosthesis.
For mechanical valves the best index is seen with bilea-
flet prostheses: 0.41±0.12; for tilting disc prostheses the
PI is 0.33±0.06, and for ball prostheses it is 0.29±0.069.
The value is even higher for bioprostheses, especially
homografts: 0.56±0.10.
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.the presence of intra- or para-prosthetic regurgitations
which must always be investigated for by continuous,
pulsed and colour Doppler. [11-15].
High transprosthetic gradients and low prosthetic surface
areas can be seen in the absence of any dysfunction if the
prosthesis/patient size match is disproportionate (“mis-
match”): the indexed valve area should be >0.9−1 cm2/m2.
Mismatch is present if it is <0.85 cm2/m2 [13] and is severe
if the indexed surface area is <0.6 cm2/m2. Gradients may
also be elevated in high cardiac output. Conversely, with
low cardiac output, a low gradient can not exclude a pros-
thetic dysfunction.
However the finding of a high gradient and low prosthetic
surface area with Doppler is not synonymous with stenosis
of the prosthesis. “Falsely elevated” gradients can be seen
on Doppler. This gradient over-estimation phenomenon on
Doppler compared to the invasive haemodynamic gradient
is especially frequent with bileaflet mechanical aortic pros-
theses but is also possible with all types of prosthesis, inclu-
ding bioprostheses [14]. The problem is due to the diffe-
rence in gradient measurement site between Doppler and
haemodynamics and is explained by the pressure recovery
phenomenon. With bileaflet prostheses, Doppler records
localised high velocity flows in the central orifice of the
prosthesis whereas velocities are lower in the lateral orifi-
ces [16, 17]. In the absence of a baseline record, interpre-
tation of a high gradient on a mechanical aortic prosthesis
is impossible and requires more investigations such as by
radio-cinema of the prosthesis and, depending on clinical
context, transoesophageal echocardiography.
Apart from these specific problems which are now clearly
understood and are associated with the architecture and
small size of some prostheses there are considerable in vivo
and in vitro data to confirm the reliability of gradient and
surface area measurements as follow-up parameters for
prosthetic valves [18].
The use of systematic post-operative
transoesophageal echocardiography
Some publications have described early abnormalities
after mitral valve replacement [19]; they included non-
obstructive thrombi, fibrin strands, and more rarely obs-
tructive thrombi [20-23]. Physiological regurgitations are
not accessible to transthoracic echocardiography which
also fails to identify small para-prosthetic regurgitations
that are important to record for the patient follow-up in
the event of subsequent complications. Some authors have
therefore proposed systematic transoesophageal echocar-
diography during the months following mitral valve repla-
cement [19-23].
Conversely, there is no need to a systematic transoeso-
phageal echocardiography in the post-operative period
after isolated aortic valve replacement if not combined
with replacement of the ascending aorta.
Mitral and aortic repair, mitral and aortic homografts
Because of the complexity of these procedures a control
transoesophageal echocardiography is required in the ope-
rating theatre to confirm the quality of functional results
and to re-operate in the same procedure if a problem exists
in order to ensure an optimal result.
Patients who undergo a mitral or much less frequently
aortic repair or homograft insertion (aortic or more rarely
mitral) should undergo post-operative transthoracic Dop-
Table 1 Mitral prostheses: essential parameters to record.
Parameter Normal value Technical comments Diagnostic value
Mean gradient 5±3 mmHg
Pathological if >10 mmHg
Variable with rate, rhythm, output +++
Pressure Half Time (PHT) 70-100 msec
Pathological if >150 msec
Do not extrapolate for surface area +++
Regurgitations — Intraprosthetic
— Paraprosthetic
TOE > TTE ++
Table 2 Aortic prostheses: essential parameters to record.
Parameter Normal value Technical comments Diagnostic value
Mean gradient <30 mmHg Variable with type and size ++ of the prosthesis +++




Indexed prosthesis surface area 
0.9-2.2 cm2 If sinus rhythm ++
regurgitations — Intraprosthetic
— Paraprosthetic 
TTE > TOE  ++
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pler echocardiography during the three months following
surgery to precise their valve statement, the existence of
any residual regurgitation and to investigate for a left intra-
ventricular obstruction due to post-operative anterior
mitral systolic movement following mitral valvuloplasty.
Follow-up beyond the 3rd month
Doppler echocardiography is the only truly reliable follow-
up investigation for prosthetic valves both in routine use
and in the event of dysfunction. In addition, in the absence
of dysfunction, the baseline Doppler haemodynamic assess-
ment of prosthetic valves is highly reproducible. As a result,
any changes in follow-up parameters found under similar
haemodynamic conditions, even if minimal, must be taken
into account in the subsequent follow-up [4].
Mechanical prostheses 
Once a baseline record has been obtained during the first 3
post-operative months, Doppler echocardiography follow-up
is indicated every 2 years in the absence of any new clinical
findings. This record should be compared with the post-ope-
rative findings and interpreted according to changes in left
ventricular function, heart rhythm and/or treatment. 
A three-monthly control of mechanical prostheses is man-
datory during pregnancy: this is justified by the increased
follow-up required because of changes in haemodynamics
and anti-coagulation modalities during pregnancy.
Mechanical prostheses are rarely implanted in the tricuspid
position because of their high thrombogenic potential: annual
Doppler echocardiography is appropriate in these cases.
Biological prostheses 
Follow-up every 2 years is appropriate in the absence of
any new clinical or laboratory event: because of the
potential degeneration specific to the bioprostheses, and
adverse haemodynamic changes after the 5th year of
implantation, annual follow-up is required beyond this
time [8]. The frequency of controls should be determined
Indications for transthoracic Doppler ultrasonography in
the initial assessment (first 3 months) of normal prosthe-
tic valves
Class I
—  Post-operative examination before discharge from 
hospital
— Reference examination within 3 months of surgery in 
patients considered as normal 
Indications for transoesophageal echocardiography in
the initial assessment (first 3 months) of normal pros-
thetic valves 
Class I
— Assessment of atrial arrhythmias when cardioversion is 
being considered in a non-anticoagulated or poorly anti-
coagulated patient.
— Suspected infectious endocarditis 
Class II
— Per-operative transoesophageal echocardiography in 
mitral valve replacement with conservation of the sub-
valvular apparatus. 
— Assessment after mitral valve replacement with a 
mechanical or biological prosthesis: investigation for 
para-prosthetic regurgitations, obstructive and/or non 
obstructive thrombi and/or strands, identification of 
physiological regurgitations.
— Assessment after aortic valve replacement combined 
with ascending aortic surgery or surgery for infectious 
endocarditis. 
— Atrial arrhythmias when cardioversion is being consi-
dered in a well anticoagulated patient.
Class III
Assessment after aortic valve replacement when trans-
thoracic Doppler echocardiography is normal.
Indications for Doppler echocardiography in the initial
assessment (first 3 months) of mitral and aortic repairs
and normal aortic and mitral homografts
Class I
— Per-operative transoesophageal echocardiography to 
guide the valve repair procedure.
— Per-operative transoesophageal echocardiography 
during mitral or aortic homograft insertion
— Baseline transthoracic Doppler echocardiography in 
the 3 months following mitral repair or homograft.
Class Il
— Transoesophageal echocardiography if the mechanism 
and/or quantification of possible residual mitral regurgi-
tation are not well identified by transthoracic Doppler 
echocardiography.
Indications for transthoracic Doppler echocardiography
in the follow-up (beyond 3 months) of normal mechani-
cal prostheses
Class I
— Control every 2 years, in the absence of any new clini-
cal or biological event.
— Control every 3 months during pregnancy because of 
physiological changes and changes in anti-coagulation 
modalities.
Class Il
— Annual control if patient is unable to correctly follow 
his/her anti-coagulation treatment.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of normal mechanical
prostheses
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
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on an individual basis depending on the extent of dysfunc-
tion of the bioprosthesis until the time of reoperation.
Annual transthoracic Doppler echocardiography is man-
datory from the year of the procedure onwards if the
patient is under 40 years.
Valve repairs and homografts
A Doppler echocardiography control every 2 years is indi-
cated for mitral and aortic repairs with no significant resi-
dual regurgitations. If a moderate or severe residual
mitral or aortic leak is present, the situation is the same
as for the follow-up of moderate or severe mitral or aortic
regurgitation.
Aortic homografts are mostly indicated in young people
and in the treatment of endocarditis. The long-term out-
come of the latest generation of homografts is not yet
known [24]. The follow-up for aortic homografts can reaso-
nably be based on that of the aortic bioprostheses.
One elective indication for the mitral homografts is inability
to perform mitral valvuloplasty [25]. There are still too few
cases of these for their follow-up to be defined.
Complications of valve prosthesis, 
valve repair and homografts
These are suggested by signs of dysfunction (abnormal
murmur, arterial embolism, endocarditis, haemolysis).
Thrombo-embolic complications 
Obstructive prostheses thrombosis
The incidence of obstructive thromboses in prostheses
varies from 0.3 to 1.3 per 100 patient-years in the litera-
ture. The main factors responsible for thromboses are ina-
dequate anti-coagulation and the mitral localization. Bio-
prostheses are not free from this type of complication
[26], although thrombosis occurs mainly in mechanical pros-
theses. Despite recent advances in bio-compatibility and
haemodynamic profile all kinds of prostheses are likely to
thrombose.
If prosthesis thrombosis is clinically suspected, auscul-
tation may reveal anomalies (occurence of an abnormal
murmur, reduction in prosthetic sounds). Radio-cinema of
the prosthesis is particularly useful in this situation revea-
ling sometimes blockage or reduced motion of a mobile
part. Doppler echocardiography is the investigation of
choice to provide a reliable, rapid and inexpensive diagno-
sis [27, 28]..For mitral prostheses, transthoracic echocardiography
often allows the diagnosis to be made from the pre-
sence of reduced motion of the mobile part and occasio-
nally from direct visualisation of a thrombus. Colour
Doppler is also extremely valuable, showing frequently
an abnormal eccentric left ventricular filling jet. Conti-
nuous mode Doppler however has the most important
role, showing an obstructive haemodynamic profile with
elevated early diastolic velocity, elevated mean gra-
dient, prolongation of the PHT, reduction in functional
surface area if this can be calculated and appearance of
an intraprosthetic leak compared to the baseline trace
[5].
Whilst the positive diagnosis of obstruction is confirmed
by transthoracic Doppler echocardiography, the aetiolo-
gical diagnosis can only be made by transoesophageal
echocardiography [27-29]. Thrombosis of the prosthesis
must be distinguished from other causes of obstruction
such as an endocarditis vegetation, fibrous pannus
(these 2 situations are often difficult to distinguish), or
blockage of a cusp by the mitral subvalvular apparatus,
when it has been preserved [30]. .Thrombosis is a clinically rare situation with aortic pros-
theses. Diagnosis is based on CW-Doppler which shows a
rise of transthoracic gradients, a fall in the permeability
Indications for transthoracic Doppler echocardiography in
the follow-up (beyond 3 months) of biological prostheses
Class I
— Control every 2 years, in the absence of any new clini-
cal or biological event.
— Annual control from year 5 in the absence of any new 
clinical or biological event.
— Annual control in subjects under 40 years.
Class II
— Annual control in elderly patients and for biological 
prostheses less than 5 years.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of biological prostheses
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
Indications for transthoracic Doppler echocardiography
in the follow-up (beyond 3 months) of valve repairs and
homografts 
Class I
— Initial control at the end of the first year in the 
absence of any new clinical biological event.
— Control every 2 years in the absence of any new, clini-
cal or biological event.
Class II
— Systematic annual control in the absence of any new, 
clinical or biological event.
Indications for transoesophageal echocardiography in
the follow-up (beyond 3 months) of valve repairs and
homografts
Class III
— Transoesophageal echocardiography if transthoracic 
Doppler echocardiography is normal in a clinically stable 
patient
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index and a reduction in functional surface area. These
abnormalities are of great value if they can be compared
with previously normal results, which again highlights the
importance of having a baseline investigation. Transoe-
sophageal echocardiography is less effective than in
prosthetic mitral valve thrombosis: it can however assess
the movement of the mobile components and occasio-
nally directly visualise a thrombus. Radio-cinema of the
prosthesis must also be performed if the echocardiogra-
phy is equivocal. 
Non-obstructive prosthesis thrombosis and embolus
The annual risk of embolism in patients with prosthetic val-
ves varies depending on authors [26, 30] from 0.7 to 6 per
100 patient-years: the risk is high for mitral prostheses and
when concomitant atrial fibrillation is present. Cerebral or
peripheral embolism may occur in the context of obstruc-
tive prosthetic dysfunction but may also be seen in cases of
non-obstructive thrombosis, intra-atrial thrombosis [29] or
even endocarditis (septic embolus).
Non-obstructive thrombosis appears to be particularly
common in the immediate post-operative period when it
can be screened for by systematic transoesophageal echo-
cardiography. After the post-operative period, in the pre-
sence of peripheral embolism in a patient with a normally
functioning prosthetic valve at the tranthoracic echocardio-
gram, only multiplane transoesophageal echocardiography
can reveal non-obstructive thrombosis or left intra-atrial
thrombus [22, 29-31]. Transoesophageal echocardiography
also provides information about the size of the prosthesis
thrombus, a factor involved in the choice of treatment [32].
Bioprosthetic failure
More than 30% of bioprostheses require valve replacement
10 to 15 years after implantation.
This time is usually shorter in patients under 40 years and
with prostheses implanted in the mitral position [3]. Regar-
dless of the type of dysfunction, stenosis or regurgitation,
the diagnosis sometimes suggested by auscultation relies on
transthoracic Doppler echocardiography, which quantifies
the dysfunction and its haemodynamic repercussions. The
investigation is usually sufficient to provide all of the infor-
mation required for reoperation. Transoesophageal echo-
cardiography is only needed if the results of transthoracic
Doppler echocardiography are inconclusive or in specific
clinical situations (occurrence of or change of a pre-existing
murmur, fever, arterial embolism, congestive heart failure,
haemolysis).
Echocardiography generally shows morphological abnor-
malities of the prosthetic cusps which are thickened and
calcified and poorly mobile, occasionally with prolapse or
eversion of a cusp. Doppler may show chronic obstruction of
the prosthesis (with raised gradients, prolongation of the
PHT and reduced prosthetic surface areas) or moderate or
occasionally massive intraprosthetic leak in the event of
sudden rupture of a cusp.
Dehiscence of a prosthesis 
This is a serious complication which is particularly common
with repeated procedures which damage the valve annnuli
[33, 34]. It affects both bioprostheses and mechanical pros-
theses without distinction and may or may not be due to
infectious endocarditis.
In the aortic position, the diagnosis and quantification of
the leak are based on transthoracic Doppler echocardiogra-
phy. Transoesophageal echocardiography is indicated for
suspected endocarditis (examination for aortic wall abs-
cess), in the event of concomitant surgery on the ascending
Indications for transthoracic Doppler echocardiography
in thrombo-embolic complications
Class I
— Assessment of suspected or overt thrombosis of a pros-
thetic valve.
— Control after increasing anti-coagulation treatment or 
thrombolysis (the frequency of subsequent investigations 
should be determined on an individual case basis).
Indications for transoesophageal echocardiography in
thrombo-embolic complications 
Class I
— Assessment in clinically suspected prosthetic valve 
thrombosis as a systematic complement to transthoracic 
Doppler echocardiography, even if normal.
— Follow-up of a non-obstructive thrombosis remaining 
asymptomatic (the frequency of subsequent investiga-
tions should be determined on an individual basis)
Indications for transthoracic Doppler echocardiography
in structural valve deterioration (svd) of bioprostheses
Class I
— Diagnosis of SVD of bioprostheses suspected from the 
occurence of or change in a pre-existing murmur, appa-
rition of fever, arterial embolism, congestive heart 
failure or haemolysis.
— Follow-up of diagnosed SVD of a bioprosthesis (the 
frequency of subsequent investigations is guided by 
the quality of the initial results depending on the 
extent of bio-prosthesis dysfunction and its haemodyna-
mic consequences, until the time of reoperation).
Consensus indications for transoesophageal echocardio-
graphy in structural valve deterioration of bioprostheses 
Class I
— Assessment if transthoracic Doppler echocardiography 
does not provide the necessary information for a treat-
ment decision. 
Class II
— Assessment if transthoracic Doppler echocardiography 
does not identify the mechanism of the regurgitation (dege-
neration, dehiscence of the bioprosthesis and/or endo-
carditis). 
Class III
— Repeat investigation in the absence of a change in cli-
nical situation or haemodynamic parameters assessed by 
transthoracic Doppler echocardiography.
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aorta and if regurgitation increases over time. Some speci-
fic complications (aortic root abscess, perivalvular
damage,..) are sometimes difficult to asses by transthora-
cic Doppler echocardiography.
In the mitral position, para-prosthetic regurgitations can
be missed by transthoracic Doppler echocardiography
because of the acoustic shadow of the prosthesis. Diagnosis
and quantification of these para-prosthetic regurgitations
are then based on multiplane transoesophageal echocardio-
graphy [26, 33, 34].
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CHRONIC ISCHAEMIC HEART DISEASE
Transthoracic Doppler echocardiography (TTE) is the pre-
ferred tool for the diagnosis and follow-up of patients with
chronic ischaemic heart disease. TTE enables repeated
study of global and regional left ventricular systolic func-
tion, left ventricular remodelling and its consequences,
analysis of left ventricular filling and assessment of pulmo-
nary pressures. The investigation therefore provides consi-
derable useful information to adjust medical treatment,
monitor evolution and assess prognosis. Systematic control
of these parameters is useful in patients with abnormal left
ventricular systolic function even if no clinical changes
have occurred. Conversely, clinical symptoms guide the fre-
quency of Doppler echocardiography controls in patients
with good left ventricular function.
Resting Doppler echocardiography 
Left ventricular geometry and function (table 1)
Left ventricular morphology. 
Investigation for left intraventricular thrombus 
(cf acute coronary syndrome chapter)
The global morphology of the left ventricle is assessed by
two-dimensional echocardiography. Ventricular diameters
are measured systematically, in M-mode with long axis
parasternal or subcostal views. 
Global left ventricular remodelling can be assessed by
measuring volumes (Simpson biplane rule) and by measu-
ring the sphericity indices obtained in systole and diastole
(ratio of maximum length of the left ventricle to its width
in the apical view) [1-4].
Left ventricular aneurysm is characterised by deformity
of the diastolic outline in an akinetic or dyskinetic area
with a thin wall. The functional value of the residual normal
myocardium must be stated [5].
The investigation should always seek to identify a left intra-
ventricular thrombus. This is particularly common as a sequela
to anterior or apical infarction with an apical aneurysm [6]
(table 2).
Left ventricular systolic function
The assessment of regional left ventricular function involves
describing akinetic or hypokinetic areas in different views,
describing their extent, morphological features and segmen-
tal wall thickness. A thin (diastolic thickness <6 mm) and
dense appearance of akinetic myocardium indicates fibrous
scarring and is highly predictive of lack of viability [7].
Estimation of left ventricular ejection fraction (LVEF) by
two-dimensional echocardiography is part of the routine
investigation. The resting LVEF is the most important pro-
gnostic indicator in patients with chronic ischaemic heart
disease and plays an important role in treatment decisions,
including consideration for cardiac resynchronisation [8, 9].
Semi-quantitative visual assessment of the LVEF has the
major limitation of limited reproducibility, particularly for
low LVEF. LVEF is best measured by the modified Simpson
biplane method using harmonic imaging. This method also
has limitations in detecting the left ventricular endocar-
dium or left ventricular dilatation. Other techniques which
are not used routinely improve the repeatability and repro-
ducibility of measurements, such as the use of intravenous
contrast agents [10] or real time transthoracic three-
dimensional echocardiography, which has recently been
introduced [11].
Left ventricular filling pressures (table 3)
(cf recommendations on the echocardiographic
assessment of cardiomyopathies) 
Evaluation of diastolic function is essential. This enables fil-
ling pressures to be measured and provides prognostic
information. 
Transmitral flow analysis by pulsed Doppler is performed
routinely. An E wave deceleration time of <150 msec and/or
E/A ratio of >2 support raised left ventricular filling pressures
in the presence of left ventricular systolic dysfunction [12-16].
Other parameters need to be recorded if mitral flow is “nor-
mal” in appearance: Ea wave measurement by tissue Doppler
at the annulus with calculation of the E/Ea ratio; pulmonary
vein flow by pulsed Doppler (Ap-Am time); left ventricular
flow propagation during early filling by colour M-mode (Vp).
Functional mitral regurgitation 
Functional mitral regurgitation is often found in heart
failure. It is dynamic in nature and may increase or reduce
as a result of changes in left ventricular size, geometry and
load conditions. Left ventricular dilatation causes apical
and lateral displacement of the papillary muscles,
increasing the papillary muscle — valve annulus distance
[17]. Increased tension on the cordae is responsible for
valve restriction, apical displacement of the closure point
and reduced closure surface area resulting in an increase in
the surface area between the mitral cusps and the annulus
in mid-systole (area under the tent) and the height of the
closure point. These geometrical and contractile changes
cause imbalance between the traction and closure forces
on the mitral valve. During ventricular systole, the mitral
valve is subjected to two competing forces: closure forces
which are represented by left intraventricular pressure and
by systolic contraction of the annulus (reducing the annulus
surface area to be covered by the mitral cusps) and the
